Latigo Biotherapeutics Appoints Todd Smith to its Board of Directors
Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the appointment of Todd Smith as an independent director on the Company’s board of directors. Mr. Smith is chief executive officer (CEO) of Corium and brings more than three decades of executive leadership and commercial experience across the biotechnology and pharmaceutical industries.
Latigo Biotherapeutics Appoints Sara M. Bonstein to its Board of Directors and as Audit Committee Chair
Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the appointment of Sara M. Bonstein as an independent director on the Company’s board of directors and as chairperson of the board’s audit committee. Ms. Bonstein is the chief financial officer of Insmed Incorporated (Insmed), and brings more than two decades of executive and financial leadership experience across biotechnology companies.
Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer and Chief Business Officer
Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, today announced that Neha Krishnamohan has been appointed as chief financial officer (CFO) and chief business officer. Ms. Krishnamohan brings more than 15 years of experience in healthcare investment banking, corporate finance, and strategic leadership, with deep expertise in driving value for growth-stage biopharmaceutical companies. Until recently, she was the audit committee chair on Latigo’s board of directors.
